Tinlarebant + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stargardt Disease 1
Conditions
Stargardt Disease 1
Trial Timeline
Mar 28, 2022 → Sep 12, 2025
NCT ID
NCT05244304About Tinlarebant + Placebo
Tinlarebant + Placebo is a phase 3 stage product being developed by Belite Bio for Stargardt Disease 1. The current trial status is completed. This product is registered under clinical trial identifier NCT05244304. Target conditions include Stargardt Disease 1.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06388083 | Phase 2/3 | Active |
| NCT05949593 | Phase 3 | Active |
| NCT05244304 | Phase 3 | Completed |
Competing Products
9 competing products in Stargardt Disease 1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 41 |
| avacincaptad pegol + Sham | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 41 |
| hESC-RPE | Astellas Pharma | Pre-clinical | 23 |
| SAR422459 | Sanofi | Phase 1/2 | 40 |
| Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Sanofi | Phase 2 | 51 |
| tinlarebant | Belite Bio | Phase 1/2 | 38 |
| OCU410ST | Ocugen | Phase 2/3 | 60 |